BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 26839173)

  • 21. The VHL gene is epigenetically inactivated in pheochromocytomas and abdominal paragangliomas.
    Andreasson A; Kiss NB; Caramuta S; Sulaiman L; Svahn F; Bäckdahl M; Höög A; Juhlin CC; Larsson C
    Epigenetics; 2013 Dec; 8(12):1347-54. PubMed ID: 24149047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SDHD immunohistochemistry: a new tool to validate SDHx mutations in pheochromocytoma/paraganglioma.
    Menara M; Oudijk L; Badoual C; Bertherat J; Lepoutre-Lussey C; Amar L; Iturrioz X; Sibony M; Zinzindohoué F; de Krijger R; Gimenez-Roqueplo AP; Favier J
    J Clin Endocrinol Metab; 2015 Feb; 100(2):E287-91. PubMed ID: 25405498
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pediatric paraganglioma: an early manifestation of an adult disease secondary to germline mutations.
    Mora J; Cascón A; Robledo M; Catala A
    Pediatr Blood Cancer; 2006 Nov; 47(6):785-9. PubMed ID: 16304664
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic status determines
    Tiwari A; Shah N; Sarathi V; Malhotra G; Bakshi G; Prakash G; Khadilkar K; Pandit R; Lila A; Bandgar T
    J Med Imaging Radiat Oncol; 2017 Dec; 61(6):745-752. PubMed ID: 28585398
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integrative analysis of miRNA and mRNA expression profiles in pheochromocytoma and paraganglioma identifies genotype-specific markers and potentially regulated pathways.
    de Cubas AA; Leandro-García LJ; Schiavi F; Mancikova V; Comino-Méndez I; Inglada-Pérez L; Perez-Martinez M; Ibarz N; Ximénez-Embún P; López-Jiménez E; Maliszewska A; Letón R; Gómez Graña A; Bernal C; Alvarez-Escolá C; Rodríguez-Antona C; Opocher G; Muñoz J; Megias D; Cascón A; Robledo M
    Endocr Relat Cancer; 2013 Aug; 20(4):477-93. PubMed ID: 23660872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of HIF-1alpha, HIF-2alpha (EPAS1), and their target genes in paraganglioma and pheochromocytoma with VHL and SDH mutations.
    Pollard PJ; El-Bahrawy M; Poulsom R; Elia G; Killick P; Kelly G; Hunt T; Jeffery R; Seedhar P; Barwell J; Latif F; Gleeson MJ; Hodgson SV; Stamp GW; Tomlinson IP; Maher ER
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4593-8. PubMed ID: 16954163
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours.
    Tsang VH; Dwight T; Benn DE; Meyer-Rochow GY; Gill AJ; Sywak M; Sidhu S; Veivers D; Sue CM; Robinson BG; Clifton-Bligh RJ; Parker NR
    Endocr Relat Cancer; 2014 Jun; 21(3):415-26. PubMed ID: 24623741
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Germline FH mutations presenting with pheochromocytoma.
    Clark GR; Sciacovelli M; Gaude E; Walsh DM; Kirby G; Simpson MA; Trembath RC; Berg JN; Woodward ER; Kinning E; Morrison PJ; Frezza C; Maher ER
    J Clin Endocrinol Metab; 2014 Oct; 99(10):E2046-50. PubMed ID: 25004247
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic and epigenetic differences of benign and malignant pheochromocytomas and paragangliomas (PPGLs).
    Khatami F; Mohammadamoli M; Tavangar SM
    Endocr Regul; 2018 Jan; 52(1):41-54. PubMed ID: 29453919
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting pheochromocytoma/paraganglioma with polyamine inhibitors.
    Rai SK; Bril F; Hatch HM; Xu Y; Shelton L; Kalavalapalli S; Click A; Lee D; Beecher C; Kirby A; Kong K; Trevino J; Jha A; Jatav S; Kriti K; Luthra S; Garrett TJ; Guingab-Cagmat J; Plant D; Bose P; Cusi K; Hromas RA; Tischler AS; Powers JF; Gupta P; Bibb J; Beuschlein F; Robledo M; Calsina B; Timmers H; Taieb D; Kroiss M; Richter S; Langton K; Eisenhofer G; Bergeron R; Pacak K; Tevosian SG; Ghayee HK
    Metabolism; 2020 Sep; 110():154297. PubMed ID: 32562798
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pheochromocytoma/Paraganglioma: Is This a Genetic Disorder?
    Fishbein L
    Curr Cardiol Rep; 2019 Jul; 21(9):104. PubMed ID: 31367972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genotype-Dependent Brown Adipose Tissue Activation in Patients With Pheochromocytoma and Paraganglioma.
    Puar T; van Berkel A; Gotthardt M; Havekes B; Hermus AR; Lenders JW; van Marken Lichtenbelt WD; Xu Y; Brans B; Timmers HJ
    J Clin Endocrinol Metab; 2016 Jan; 101(1):224-32. PubMed ID: 26574955
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent Advances in Histopathological and Molecular Diagnosis in Pheochromocytoma and Paraganglioma: Challenges for Predicting Metastasis in Individual Patients.
    Yamazaki Y; Gao X; Pecori A; Nakamura Y; Tezuka Y; Omata K; Ono Y; Morimoto R; Satoh F; Sasano H
    Front Endocrinol (Lausanne); 2020; 11():587769. PubMed ID: 33193100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical implications of the oncometabolite succinate in SDHx-mutation carriers.
    Eijkelenkamp K; Osinga TE; Links TP; van der Horst-Schrivers ANA
    Clin Genet; 2020 Jan; 97(1):39-53. PubMed ID: 30977114
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MAX mutations status in Swedish patients with pheochromocytoma and paraganglioma tumours.
    Crona J; Maharjan R; Delgado Verdugo A; Stålberg P; Granberg D; Hellman P; Björklund P
    Fam Cancer; 2014 Mar; 13(1):121-5. PubMed ID: 23743562
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exosomal double-stranded DNA as a biomarker for the diagnosis and preoperative assessment of pheochromocytoma and paraganglioma.
    Wang L; Li Y; Guan X; Zhao J; Shen L; Liu J
    Mol Cancer; 2018 Aug; 17(1):128. PubMed ID: 30139385
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas.
    Fishbein L; Khare S; Wubbenhorst B; DeSloover D; D'Andrea K; Merrill S; Cho NW; Greenberg RA; Else T; Montone K; LiVolsi V; Fraker D; Daber R; Cohen DL; Nathanson KL
    Nat Commun; 2015 Jan; 6():6140. PubMed ID: 25608029
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic testing in the clinical care of patients with pheochromocytoma and paraganglioma.
    Rana HQ; Rainville IR; Vaidya A
    Curr Opin Endocrinol Diabetes Obes; 2014 Jun; 21(3):166-76. PubMed ID: 24739310
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular markers of paragangliomas/pheochromocytomas.
    Zhikrivetskaya SO; Snezhkina AV; Zaretsky AR; Alekseev BY; Pokrovsky AV; Golovyuk AL; Melnikova NV; Stepanov OA; Kalinin DV; Moskalev AA; Krasnov GS; Dmitriev AA; Kudryavtseva AV
    Oncotarget; 2017 Apr; 8(15):25756-25782. PubMed ID: 28187001
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TMEM127 screening in a large cohort of patients with pheochromocytoma and/or paraganglioma.
    Abermil N; Guillaud-Bataille M; Burnichon N; Venisse A; Manivet P; Guignat L; Drui D; Chupin M; Josseaume C; Affres H; Plouin PF; Bertherat J; Jeunemaître X; Gimenez-Roqueplo AP
    J Clin Endocrinol Metab; 2012 May; 97(5):E805-9. PubMed ID: 22419703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.